Translational Regulators in Pulmonary Fibrosis: MicroRNAs, Long Non-Coding RNAs, and Transcript Modifications

Area of Science:

• * Molecular Biology
• * Pulmonary Medicine
• * Genetics

Background:

• * Fibrosing disorders, such as idiopathic pulmonary fibrosis (IPF), are characterized by progressive, irreversible scarring and extracellular matrix accumulation, often leading to poor prognoses.
• * Gene expression is critically controlled by translational regulation, and its dysregulation is implicated in IPF pathogenesis.
• * Understanding translational regulators is key to developing effective IPF therapies.

Purpose of the Study:

• * To review the current literature on translational regulators in IPF.
• * To focus on the roles of microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and RNA transcript modifications (alternative polyadenylation, chemical modification) in IPF.
• * To explore the potential of targeting these regulators for IPF therapeutics.

Main Methods:

• * Comprehensive literature review of translational regulation in IPF.
• * Analysis of the roles of specific translational regulators, including miRNAs and lncRNAs.
• * Examination of RNA transcript modifications such as alternative polyadenylation and chemical modifications.

Main Results:

• * Translational regulators significantly influence fibrosis, with some promoting and others inhibiting the process.
• * In IPF, profibrotic regulators are often upregulated, while antifibrotic regulators are downregulated.
• * Specific miRNAs, lncRNAs, and RNA modifications are identified as key players in IPF-associated fibrosis.

Conclusions:

• * Dysregulated translational regulators are central to IPF pathogenesis.
• * Targeting aberrant profibrotic and antifibrotic regulators presents a promising therapeutic strategy for IPF.
• * Further research into these regulators could unlock novel treatments for fibrosing lung diseases.